Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-UK PM Johnson wants 'cautious but irreversible' path out of COVID-19 lockdown

Mon, 15th Feb 2021 07:43

* UK hits 15 million vaccination target

* Johnson: lockdown exit will be cautious but irreversible

* Vaccine certificates will happen - Johnson

* Johnson to judge this week on lockdown exit
(Recasts headline and lead)

By Guy Faulconbridge and Kate Holton

LONDON, Feb 15 (Reuters) - British Prime Minister Boris
Johnson said on Monday he would plot a cautious but irreversible
path out of the COVID-19 lockdown this week after the
vaccination of 15 million vulnerable people.

With nearly a quarter of the United Kingdom's population now
inoculated with a first dose of a COVID vaccine in a little over
two months, Johnson is under pressure from some lawmakers and
businesses to reopen the shuttered economy.

"We've got to be very prudent and what we want to see is
progress that is cautious, but irreversible," Johnson told
reporters. "If we possibly can, we'll be setting out dates."

"If because of the rate of infection, we have to push off
something a little bit to the right - delay it for a little bit
- we won't hesitate to do that."

Johnson, due to set the path out of lockdown on Feb. 22,
said the rates of infection were still high and too many people
were still dying.

Asked if he would ensure schools reopened on March 8,
Johnson said he would do everything he could to ensure that.

If many people get infected, there would be a high risk of
mutation in the virus and higher risk of it spreading to older
and more vulnerable groups, he said.

The biggest and swiftest global vaccine rollout in history
is seen as the best chance of exiting the COVID-19 pandemic
which has killed 2.4 million people, tipped the global economy
into its worst peacetime slump since the Great Depression, and
upended normal life for billions.

The United Kingdom has the world's fifth-worst official
death toll - currently 117,166 - after the United States,
Brazil, Mexico and India.

VACCINE PASSPORTS?

Britain has vaccinated 15.062 million people with a first
dose and 537,715 with a second dose, the fastest rollout per
capita of any large country. Hancock said he expected vaccine
supplies to increase as manufacturing accelerated.

An influential group of lawmakers in Johnson's Conservative
Party is urging an end to the lockdown as soon as the most
vulnerable nine groups are vaccinated. They want no more rules
beyond May 1.

"We're all filled with sorrow for the people we've lost, the
harms that we've suffered but we don't honour those we've loved
and lost by wrecking the rest of our lives," lawmaker Steve
Baker said. "We've got to find a way to rebuild our society and
our economy and our prospects, our livelihoods."

Britain is speaking to other countries about giving its
citizens certificates showing they have been vaccinated so that
they can travel abroad in the future to countries that require
them, Johnson said.

"That's going to be very much in the mix, down the road I
think that is going to happen," Johnson said, referring to such
certificates. "What I don't think we will have in this country
is, as it were, vaccination passports to allow you to go to the
pub, or something like that."
(Reporting by Guy Faulconbridge and Kate Holton; Editing by
Peter Graff, Nick Macfie and Bernadette Baum)

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.